2 news items
Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
CHRS
9 May 24
, assets derecognized, transactions costs of $7.2 million and other employee transition related expenses. Net income
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
CHRS
13 Mar 24
to result in a reduction in workforce of 30% by the end of 2024, including 35 employees associated with the ophthalmology divestiture, for an estimated
- Prev
- 1
- Next